ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial Cancer
Status:
Recruiting
Trial end date:
2022-02-28
Target enrollment:
Participant gender:
Summary
This is a a Simon's two-stage, non-randomized, open label, 2-arm Phase II trial of ONC201 in
women with metastatic or recurrent Type II endometrial cancer who failed at least 1 prior
chemotherapy regimen.